Evidence map›Paper›PMID 42160298›Full record

ArticlePLoS pathogens2026

Tripartite motif-containing 34 (TRIM34) protein interacts with the nucleocytoplasmic transport machinery and negatively modulates antiviral responses.

Paula Vázquez-Utrilla, Vanessa Rivero, Marta L DeDiego

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Paula Vázquez-UtrillaDepartment of Molecular and Cell Biology, Centro Nacional de Biotecnología-Consejo Superior de Investigaciones Científicas (CNB-CSIC), Madrid, Spain.
Vanessa RiveroDepartment of Molecular and Cell Biology, Centro Nacional de Biotecnología-Consejo Superior de Investigaciones Científicas (CNB-CSIC), Madrid, Spain.
Marta L DeDiegoDepartment of Molecular and Cell Biology, Centro Nacional de Biotecnología-Consejo Superior de Investigaciones Científicas (CNB-CSIC), Madrid, Spain.ORCID https://orcid.org/0000-0002-7888-7372

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tripartite motif-containing (TRIM) 34 protein is an interferon (IFN)-induced protein whose expression is upregulated after influenza A virus (IAV) infection. Here, we identify a previously unknown function for TRIM34 as a negative regulator of innate immune responses following IFN treatment and IAV infection, even in mice, suggesting that this effect is broad and conserved. Complementary overexpression and silencing experiments in cultured cells show that TRIM34 expression positively correlates with IAV titers, indicating that TRIM34 promotes viral replication, likely by counteracting antiviral responses. Moreover, we show novel interactions of TRIM34 with cellular proteins involved in the nucleocytoplasmic transport of host mRNAs and proteins, even in mock-infected cells. Remarkably, these TRIM34 interactions seem independent of TRIM34 E3 ubiquitin ligase activity and affect the nuclear import of IFN-regulatory factor 3 (IRF3) and the nuclear export of host mRNAs encoding antiviral functions, without affecting the nuclear export of viral mRNAs. These results provide a likely mechanism by which TRIM34 dampens host innate immune responses. These TRIM34-mediated effects could be further exploited to develop new antiviral drugs against IAV, and potentially other viral infections.

Indexed as

Immunity, InnateInfluenza A virusActive Transport, Cell NucleusAnimalsHumansInterferon Regulatory Factor-3MiceUbiquitin-Protein LigasesVirus ReplicationInterferon Regulatory Factor-3Ubiquitin-Protein Ligases

Identifiers

PMID42160298
PMCPMC13189347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.